Tag: ACW

Actinogen Medical ASX ACW cognitive improvement Xanamem XanaHES Alzheimer’s disease neurological

Actinogen Medical announces ‘breakthrough’ study results for Alzheimer’s drug Xanamem

Actinogen Medical (ASX: ACW) has announced “breakthrough” results from its XanaHES higher dose safety study first initiated last year. The results reaffirm the foundational hypothesis that reducing...
Actinogen Medical ASX ACW Phase 2 Alzheimer's disease trial results fail dementia

Actinogen Medical phase two Alzheimer’s clinical trial disappoints

Biotech company Actinogen Medical (ASX: ACW) has reported a mixed bag of results including some disappointing outcomes from its XanADu phase two clinical trial treating patients with mild dementia due...
Actinogen Medical ASX ACW US biotech investor Alzheimer’s XanADu study

Actinogen Medical attracts US biotech investor as Alzheimer’s XanADu study remains on track

Actinogen Medical (ASX: ACW) has received a double-shot of positive news earlier today after the biotech company received the all-clear from the Data Safety and Monitoring Board (DSMB) to continue its...
Actinogen Medical ASX ACW XanADu treat Alzheimer’s disease

Actinogen moves towards XanADu starting line to treat Alzheimer’s disease

Biotech company Actinogen Medical (ASX: ACW) has confirmed that it has obtained half of the required patients in order to conduct its landmark Phase 2 clinical trial of Xanamem, a drug candidate to tr...